CO4980849A1 - Composiciones farmaceuticas -2-hidroximetil-1,3-oxatiolan-5-il)-(1h)-pirimidin-2-ona(la mivudina), y su uso en terapia medica - Google Patents

Composiciones farmaceuticas -2-hidroximetil-1,3-oxatiolan-5-il)-(1h)-pirimidin-2-ona(la mivudina), y su uso en terapia medica

Info

Publication number
CO4980849A1
CO4980849A1 CO98015975A CO98015975A CO4980849A1 CO 4980849 A1 CO4980849 A1 CO 4980849A1 CO 98015975 A CO98015975 A CO 98015975A CO 98015975 A CO98015975 A CO 98015975A CO 4980849 A1 CO4980849 A1 CO 4980849A1
Authority
CO
Colombia
Prior art keywords
concentrations
mivudina
oxatiolan
hidroximetil
pirimidin
Prior art date
Application number
CO98015975A
Other languages
English (en)
Inventor
Thi Nguyen Ngoc-Anh
Michael Casey Warren
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9706295.4A external-priority patent/GB9706295D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO4980849A1 publication Critical patent/CO4980849A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Abstract

Una composición farmacéutica, substancialmente libre de etanol yácido etilendiaminotetraacético, caracterizada porque comprende lamivudina o un derivado farmacéuticamente aceptable de la misma, y un sistema conservador. Una composición farmacéutica, caracterizada porque comprende lamivudina, la formulación que está substancialmente libre de etanol y ácido etilendiaminatetraacético y que cumple las siguientes especificaciones: (a). Las concentraciones de las bacterias viables se reducen a no más de 0,1% de las concentraciones iniciales por el décimo cuarto día; (b). Las concentraciones de las levaduras viables y mohos permanecen en, o bajo las concentraciones iniciales durante los primeros catorce días; y (c). Las concentraciones de cada uno de los microorganismos de prueba permanecen en, o abajo de esos niveles designados durante el resto del período de prueba de 28 días.
CO98015975A 1997-03-24 1998-03-20 Composiciones farmaceuticas -2-hidroximetil-1,3-oxatiolan-5-il)-(1h)-pirimidin-2-ona(la mivudina), y su uso en terapia medica CO4980849A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4235397P 1997-03-24 1997-03-24
GBGB9706295.4A GB9706295D0 (en) 1997-03-26 1997-03-26 Lamivudine formulation

Publications (1)

Publication Number Publication Date
CO4980849A1 true CO4980849A1 (es) 2000-11-27

Family

ID=26311267

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98015975A CO4980849A1 (es) 1997-03-24 1998-03-20 Composiciones farmaceuticas -2-hidroximetil-1,3-oxatiolan-5-il)-(1h)-pirimidin-2-ona(la mivudina), y su uso en terapia medica

Country Status (40)

Country Link
US (1) US6004968A (es)
EP (1) EP0969815B1 (es)
JP (1) JP3264937B2 (es)
KR (1) KR100484695B1 (es)
CN (1) CN1191061C (es)
AP (1) AP1141A (es)
AR (1) AR011697A1 (es)
AT (1) ATE295150T1 (es)
AU (1) AU728461B2 (es)
BG (1) BG64690B1 (es)
BR (1) BR9808060B1 (es)
CA (1) CA2286126C (es)
CO (1) CO4980849A1 (es)
CY (1) CY2569B1 (es)
CZ (1) CZ298008B6 (es)
DE (1) DE69830154T2 (es)
EA (1) EA001990B1 (es)
EE (1) EE03996B1 (es)
ES (1) ES2239802T3 (es)
HK (1) HK1022853A1 (es)
HN (1) HN1998000045A (es)
HR (1) HRP980154B1 (es)
HU (1) HU225600B1 (es)
ID (1) ID29294A (es)
IL (1) IL131917A0 (es)
IS (1) IS2515B (es)
MY (1) MY116242A (es)
NO (1) NO326719B1 (es)
NZ (1) NZ337798A (es)
PA (1) PA8449301A1 (es)
PE (1) PE61699A1 (es)
PL (1) PL190505B1 (es)
PT (1) PT969815E (es)
RS (1) RS49772B (es)
SI (1) SI0969815T1 (es)
SK (1) SK283417B6 (es)
SV (1) SV1998000040A (es)
TW (1) TW536403B (es)
UY (1) UY24930A1 (es)
WO (1) WO1998042321A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9903249A3 (en) 1996-06-25 2001-04-28 Glaxo Group Ltd Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
US6018044A (en) * 1998-01-02 2000-01-25 Roche Vitamins Inc. Light screening compositions
US6432966B2 (en) * 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
JP2003039582A (ja) * 2001-07-19 2003-02-13 Three M Innovative Properties Co 湿潤防滑性シート及び湿潤防滑構造体
US6855346B2 (en) * 2001-10-05 2005-02-15 Tzu-Sheng Wu Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same
TWI275392B (en) * 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
WO2004075913A1 (ja) * 2003-02-28 2004-09-10 Chugai Seiyaku Kabushiki Kaisha タンパク質含有安定化製剤
US20040228804A1 (en) * 2003-05-16 2004-11-18 Jones Alonzo H. Nasal administration of xylitol to a non-human mammal
PE20060484A1 (es) * 2004-07-14 2006-07-06 Ucb Farchim Sa Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina
CN100427082C (zh) * 2005-08-02 2008-10-22 盛华（广州）医药科技有限公司 羟基苯甲酸酯及其类似物在制备预防和治疗病毒性感染药物中的应用
US20110117193A1 (en) * 2008-01-17 2011-05-19 Duquesne University Of The Holy Spirit Antiretroviral drug formulations for treatment of children exposed to hiv/aids
RU2587782C1 (ru) * 2015-01-19 2016-06-20 Общество с ограниченной ответственностью "Трейдсервис" Стабильная фармацевтическая композиция ламивудина

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
CZ285232B6 (cs) * 1991-05-16 1999-06-16 Glaxo Group Limited Protivirové směsi
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9503850D0 (en) * 1995-02-25 1995-04-19 Glaxo Group Ltd Medicaments
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
GB9605293D0 (en) * 1996-03-13 1996-05-15 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
TW536403B (en) 2003-06-11
ATE295150T1 (de) 2005-05-15
SI0969815T1 (es) 2005-08-31
BG103818A (en) 2000-06-30
AU728461B2 (en) 2001-01-11
JP2001501974A (ja) 2001-02-13
PT969815E (pt) 2005-07-29
ES2239802T3 (es) 2005-10-01
PL336038A1 (en) 2000-06-05
KR100484695B1 (ko) 2005-04-22
IL131917A0 (en) 2001-03-19
DE69830154T2 (de) 2005-10-13
PA8449301A1 (es) 2000-05-24
JP3264937B2 (ja) 2002-03-11
SK283417B6 (sk) 2003-07-01
EA001990B1 (ru) 2001-10-22
EE03996B1 (et) 2003-04-15
NO326719B1 (no) 2009-02-02
CZ298008B6 (cs) 2007-05-23
AP1141A (en) 2003-01-29
KR20010005624A (ko) 2001-01-15
HUP0002982A3 (en) 2001-12-28
CA2286126A1 (en) 1998-10-01
SK129999A3 (en) 2000-07-11
AR011697A1 (es) 2000-08-30
IL131917A (en) 2001-01-11
PL190505B1 (pl) 2005-12-30
BR9808060B1 (pt) 2009-05-05
IS5184A (is) 1999-09-17
EP0969815A2 (en) 2000-01-12
EE9900440A (et) 2000-04-17
NO994619D0 (no) 1999-09-23
MY116242A (en) 2003-12-31
NZ337798A (en) 2001-03-30
AU7208498A (en) 1998-10-20
CY2569B1 (en) 2008-07-02
DE69830154D1 (de) 2005-06-16
UY24930A1 (es) 2000-10-31
HRP980154A2 (en) 1998-12-31
HN1998000045A (es) 1999-03-19
IS2515B (is) 2009-06-15
WO1998042321A2 (en) 1998-10-01
CN1255849A (zh) 2000-06-07
YU47799A (sh) 2002-06-19
EA199900757A1 (ru) 2000-08-28
BG64690B1 (bg) 2005-12-30
EP0969815B1 (en) 2005-05-11
WO1998042321A3 (en) 1999-01-07
ID29294A (id) 2001-08-16
RS49772B (sr) 2008-06-05
HK1022853A1 (en) 2000-08-25
HU225600B1 (en) 2007-05-02
HUP0002982A2 (hu) 2001-01-29
SV1998000040A (es) 1999-03-16
NO994619L (no) 1999-11-23
CZ340399A3 (cs) 2000-04-12
AP9901657A0 (en) 1999-09-30
PE61699A1 (es) 1999-07-08
BR9808060A (pt) 2000-03-08
US6004968A (en) 1999-12-21
CA2286126C (en) 2003-08-12
HRP980154B1 (en) 2002-06-30
CN1191061C (zh) 2005-03-02

Similar Documents

Publication Publication Date Title
FI872864A0 (fi) Menetelmä farmaseuttisesti aktiivisten bentsimidatsolijohdannaisten valmistamiseksi
HUP0101999A2 (hu) 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
ES2082755T3 (es) Derivados de acido 3-desmetil-mevalonico, procedimiento para su preparacion, preparados farmaceuticos a base de estos compuestos, su utilizacion asi como productos intermedios.
CO4980849A1 (es) Composiciones farmaceuticas -2-hidroximetil-1,3-oxatiolan-5-il)-(1h)-pirimidin-2-ona(la mivudina), y su uso en terapia medica
DK499088D0 (da) 1-oe(2-pyrimidinyl)-aminoalkylaapiperidinderivater, fremgangsmaade til fremstilling deraf og laegemiddel indeholdende saadanne derivater
ES2108129T3 (es) Nuevos derivados de pirazina, su preparacion y empleo.
ATE38991T1 (de) In 2-stellung substituierte 1,3propyledendephosphonat-derivate, ihre herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
HUP9802861A2 (hu) Calendula glikozidok alkalmazása bőrsejtek túlburjánzásával kapcsolatos betegségek, így psoriasis kezelésére alkalmas gyógyászati készítmény előállítására, ezen vegyületek, valamint ezeket tartalmazó gyógyászati készítmények
BR0012610A (pt) Novo derivado de difenilpiperidina
DK359387A (da) Oploesninger af oxazaphosphoriner med forbedret stabilitet og fremgangsmaade til deres fremstilling
ATE2265T1 (de) Sekundaere amine, ihre herstellung und verwendung in pharmazeutischen zusammensetzungen.
DE3767114D1 (de) Stabilisierte arzneimittel.
FI854179L (fi) Antibakterieblandning och framstaellningsfoerfarande foer dess aktiva aemnen.
YU47338B (sh) Novo jedinjenje 4-fluoro-2-// (4-metoksi-2-piridinil)metil-/sulfinil/- 1h-benzimidazol i postupak za njegovo dobijanje
ATE13765T1 (de) 2-(1,4-benzodioxan-2-ylalkyl)-imidazole, deren herstellung und sie enthaltende pharmazeutische mittel.
DE3764111D1 (de) Arzneimittelkombination.
DK154385D0 (da) Tetrahydrothienopyridiner eller farmaceutisk uskadelige salte deraf, deres fremstilling og anvendelse som laegemidler
AU658175B2 (en) Use of 2-iminothiazolidin-4-one derivatives as novel pharmaceutical active ingredients
SE8004383L (sv) Farmaceutisk beredning for oral administrering och forfarande for dess framstellning
DK313587D0 (da) Tetrahydrobenzothiazolforbindelser, deres fremstilling og anvendelse
ES2160117T3 (es) Composicion farmaceutica antitumoral a base de carboplatino, y su procedimiento de produccion.
FI860098A0 (fi) Nya piperazinderivat, foerfarande foer deras framstaellning och farmaceutiska kompositioner som innehaoller dessa foereningar som aktiv ingrediens.
DK364386D0 (da) 1-alkyl-ergolinyl-thiourinstofderivater og fremgangsmaade til fremstilling deraf samt deres anvendelse
ES2121071T3 (es) Compuestos de oxazolidina y su empleo como medicamentos.